crizotinib and Empyema

crizotinib has been researched along with Empyema* in 1 studies

Other Studies

1 other study(ies) available for crizotinib and Empyema

Article	Year
Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema. Tumori, 2019, Volume: 105, Issue:6 Anaplastic lymphoma kinase (. A 41-year-old old man, former smoker, was diagnosed with NSCLC in the right lung with manifest pleural effusion. This case was complicated by a pleural empyema and because of a trapped lung, there was an indication for the construction of a thoracostomy. After confirmation of the. This case describes a relatively young patient with a poor prognosis but with a remarkable and long-term response to crizotinib monotherapy. Topics: Adult; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Empyema; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Radiography, Thoracic; Thoracostomy; Tomography, X-Ray Computed; Treatment Outcome	2019

Article

Year

Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema.

Tumori, 2019, Volume: 105, Issue:6

Anaplastic lymphoma kinase (. A 41-year-old old man, former smoker, was diagnosed with NSCLC in the right lung with manifest pleural effusion. This case was complicated by a pleural empyema and because of a trapped lung, there was an indication for the construction of a thoracostomy. After confirmation of the. This case describes a relatively young patient with a poor prognosis but with a remarkable and long-term response to crizotinib monotherapy.

Topics: Adult; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Empyema; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Radiography, Thoracic; Thoracostomy; Tomography, X-Ray Computed; Treatment Outcome

2019